What Happened?
The healthcare company Grifols announced in a recent press release that it has enrolled and dosed the very first patient in a new Phase 3 clinical trial called SWIFT-SC. This global study is testing a new way for patients with Alpha-1-antitrypsin (AAT) deficiency to receive their medication.
Instead of getting the drug through an intravenous (IV) line into a vein, this trial is testing a subcutaneous (SC) injection—meaning the medicine is injected into the fatty tissue just under the skin, similar to how insulin is given.
What is Alpha-1-Antitrypsin (AAT) Deficiency?
Alpha-1 is a genetic (inherited) condition where the body doesn’t make enough of a specific protective protein called Alpha-1-antitrypsin. Without enough of this protein, the lungs are left unprotected against inflammation, smoke, and infections. Over time, this lack of protection causes severe lung damage and can lead to Chronic Obstructive Pulmonary Disease (COPD) or emphysema, which makes it very hard to breathe.
Why is This Trial Important?
Currently, the standard treatment for Alpha-1 is “augmentation therapy,” which involves replacing the missing protein. However, the standard method requires regular IV infusions. This means patients often have to travel to a specialized clinic, wait for a nurse, or have a home-health nurse visit them, which can take hours and disrupt daily life.
The SWIFT-SC trial is a major milestone because:
- It’s a First: This is the first Phase 3 trial to look at a subcutaneous (under-the-skin) option for this treatment.
- Higher Concentration: The new formula is about three times more concentrated than the standard IV version, which allows a full dose to be given via a smaller injection under the skin.
- More Freedom: If successful, this could completely change how patients manage their condition. It opens the door for self-administration, meaning patients could potentially give themselves the medication at home on their own schedule, giving them much more independence and flexibility.
How the Study Works
The SWIFT-SC study is an “open-label” trial (meaning both the doctors and patients know which dose they are getting). It is comparing two different weekly doses of the new subcutaneous injection against the standard weekly IV doses. The main goal is to prove “non-inferiority”—meaning researchers want to show that the under-the-skin injection works just as well and stays in the body just as effectively as the traditional IV version, while also ensuring it is safe and well-tolerated.
Current Trial Status
The clinical trial is actively underway and is still recruiting patients to participate. To ensure a diverse global patient pool, the study is being conducted at 9 locations throughout Europe and Scandinavia, as well as 10 locations across the United States.
